Results
CORONA Remedies Q4 FY26 Revenue Up 20.2% YoY
CORONA Remedies reported Q4 FY26 revenue growth of 20.2% YoY to ₹353.1 Cr and FY26 growth of 17.3% to ₹1,403.2 Cr.
The company acquired Wokadine® from Dr. Reddy's and 7 brands from Bayer Zydus, expand
